From: Metabolic phenotypes in primary unknown metastatic carcinoma
Clinical parameters | Total N = 77 (%) | Histologic subtype | p-value | |||
---|---|---|---|---|---|---|
AD (n = 27) (%) | PD (n = 16) (%) | SQ (n = 20) (%) | UD (n = 14) (%) | |||
Age (years, mean ± SD) | 55.4 ± 11.8 | 59.3 ± 12.3 | 55.3 ± 12.1 | 55.0 ± 9.6 | 48.3 ± 10.6 | 0.042 |
Sex | Â | Â | Â | Â | Â | 0.521 |
 Female | 29 (37.7) | 13 (48.1) | 6 (37.5) | 6 (30.0) | 4 (28.6) |  |
 Male | 48 (62.3) | 14 (51.9) | 10 (62.5) | 14 (70.0) | 10 (71.4) |  |
Clinical subtype | Â | Â | Â | Â | Â | <0.001 |
 Nodal type | 34 (44.2) | 3 (11.1) | 8 (50.0) | 14 (70.0) | 9 (64.3) |  |
 Single organ type | 15 (19.5) | 6 (22.2) | 5 (31.3) | 0 (0.0) | 4 (28.6) |  |
 Intermediate type | 14 (18.2) | 7 (25.9) | 1 (6.3) | 5 (25.0) | 1 (7.1) |  |
 Carcinomatosis type | 14 (18.2) | 11 (40.7) | 2 (12.5) | 1 (5.0) | 0 (0.0) |  |
Organs involved | Â | Â | Â | Â | Â | 0.102 |
 Lymph node | 49 (63.6) | 12 (44.4) | 9 (56.3) | 19 (95.0) | 9 (64.3) |  |
 Bone | 10 (13.0) | 6 (22.2) | 2 (12.5) | 0 (0.0) | 2 (14.3) |  |
 Brain | 9 (11.7) | 4 (14.8) | 2 (12.5) | 1 (5.0) | 2 (14.3) |  |
 Other | 9 (11.7) | 5 (18.5) | 3 (18.8) | 0 (0.0) | 1 (7.1) |  |
Postoperative treatment | Â | Â | Â | Â | Â | 0.039 |
 None | 21 (27.3) | 8 (29.6) | 3 (18.8) | 4 (20.0) | 6 (42.9) |  |
 Chemotherapy | 24 (31.2) | 12 (44.4) | 5 (31.3) | 3 (15.0) | 4 (28.6) |  |
 Radiation therapy | 15 (19.5) | 6 (22.2) | 1 (6.3) | 6 (30.0) | 2 (14.3) |  |
 Chemo-radiation therapy | 17 (22.1) | 1 (3.7) | 7 (43.8) | 7 (35.0) | 2 (14.3) |  |